Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 97.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,719 shares of the biopharmaceutical company’s stock after selling 350,236 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Gilead Sciences were worth $672,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Altshuler Shaham Ltd grew its holdings in shares of Gilead Sciences by 7.0% in the 4th quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 121 shares during the last quarter. Intercontinental Wealth Advisors LLC increased its stake in Gilead Sciences by 2.4% in the 2nd quarter. Intercontinental Wealth Advisors LLC now owns 5,458 shares of the biopharmaceutical company’s stock worth $421,000 after purchasing an additional 126 shares in the last quarter. Baker Tilly Wealth Management LLC raised its holdings in Gilead Sciences by 2.3% during the 2nd quarter. Baker Tilly Wealth Management LLC now owns 5,694 shares of the biopharmaceutical company’s stock worth $439,000 after buying an additional 128 shares during the period. Pinkerton Retirement Specialists LLC lifted its stake in Gilead Sciences by 2.8% during the first quarter. Pinkerton Retirement Specialists LLC now owns 4,703 shares of the biopharmaceutical company’s stock valued at $390,000 after buying an additional 129 shares in the last quarter. Finally, DGS Capital Management LLC increased its position in shares of Gilead Sciences by 2.0% in the first quarter. DGS Capital Management LLC now owns 6,570 shares of the biopharmaceutical company’s stock worth $545,000 after acquiring an additional 131 shares in the last quarter. 82.33% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

NASDAQ GILD opened at $75.45 on Monday. The company has a market cap of $94.01 billion, a P/E ratio of 16.19, a P/E/G ratio of 1.00 and a beta of 0.32. Gilead Sciences, Inc. has a 1 year low of $72.87 and a 1 year high of $89.74. The company has a current ratio of 1.34, a quick ratio of 1.20 and a debt-to-equity ratio of 1.08. The company has a fifty day simple moving average of $76.82 and a 200 day simple moving average of $77.26.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $2.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.38. The company had revenue of $7.05 billion during the quarter, compared to analysts’ expectations of $6.81 billion. Gilead Sciences had a net margin of 21.45% and a return on equity of 39.30%. The business’s quarterly revenue was up .1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.90 earnings per share. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 6.76 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 3.98%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 64.38%.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. UBS Group lowered their price objective on shares of Gilead Sciences from $85.00 to $84.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 8th. Morgan Stanley upped their price target on Gilead Sciences from $86.00 to $88.00 and gave the company an “equal weight” rating in a research report on Friday, August 4th. Leerink Partnrs reaffirmed a “market perform” rating on shares of Gilead Sciences in a research note on Wednesday, October 11th. StockNews.com initiated coverage on shares of Gilead Sciences in a research report on Thursday, October 5th. They issued a “strong-buy” rating for the company. Finally, Barclays dropped their price objective on shares of Gilead Sciences from $81.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Monday, July 24th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $88.22.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 1,501 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $76.99, for a total value of $115,561.99. Following the completion of the sale, the insider now directly owns 70,130 shares of the company’s stock, valued at $5,399,308.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Andrew D. Dickinson sold 5,000 shares of the business’s stock in a transaction dated Tuesday, October 17th. The shares were sold at an average price of $80.00, for a total transaction of $400,000.00. Following the transaction, the chief financial officer now owns 104,003 shares in the company, valued at approximately $8,320,240. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Merdad Parsey sold 1,501 shares of Gilead Sciences stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $76.99, for a total value of $115,561.99. Following the sale, the insider now directly owns 70,130 shares in the company, valued at $5,399,308.70. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.